Merck Sharp + Dohme Corp.

Schering Corporation

Panduranga Adulla Reddy

M Arshad Siddiqui

Gerald Wayne Shipps, Jr

Lianyun Zhao

Binyuan Sun

Hongbo Zeng

Cliff C Cheng

Timothy J Guzi

Zhaoyang Meng

Matthew Richards

Michael P Dwyer

Yongqi Deng

Thierry Olivier Fischmann

Jose S Duca

Xiaohua Huang

Shuyi Tang

Yang Nan

Duan Liu

Praveen K Tadikonda

Tzu Tshin Wong

Kamil Paruch

Vincent Stewart Madison

Umar Faruk Mansoor

Kartik M Keertikar

Andrew J McRiner

Marc A Labroli

David Benjamin Belanger

Luis E Torres

Mehul F Patel

Iwona Wrona

Patrick J Curran

Gerald W Shipps

Blake Hamann

Amit K Mandal

Yinyan Zhao

Brian M Eklov

Cory S Poker

Andrew Mcriner

Iwona E Wrona

Marc M Labroli

Cory Poker

Jr Gerald W Shipps

The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. 

Anilinopiperazine derivatives and methods of use thereof

This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.

Fused tricyclic inhibitors of mammalian target of rapamycin

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R, R, R, and Rare as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders. 

Fused Tricyclic Compounds as novel mTOR inhibitors

The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors

The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. 

2-aminothiazole-4-carboxylic amides as protein kinase inhibitors

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-&#x3b1; or combinations thereof.

Compounds for the treatment of inflammatory disorders

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. An illustrative compound of the invention is shown below: 

Imidazopyrazines as cyclin dependent kinase inhibitors

Growing community of inventors

Walpole, MA, United States of America

Panduranga Adulla Reddy